Sign In
Buy ANIP
$75.23
+0.580 (+0.777%)
At Close: Jun 03, 2026
ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why
01:46pm, Wednesday, 25'th Mar 2026
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
02:14am, Sunday, 22'nd Mar 2026
Shares of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight research firms that are currently covering the firm, Mark
Apis Capital Advisors LLC Purchases 36,000 Shares of ANI Pharmaceuticals, Inc. $ANIP
04:08am, Sunday, 15'th Mar 2026
Apis Capital Advisors LLC raised its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) by 28.1% in the undefined quarter, according to its most recent Form 13F filing with the Securities
4 Biotech Stocks to Watch for Potential Upside in 2026
03:55pm, Friday, 13'th Mar 2026
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and soli
Wall Street Analysts See a 44.84% Upside in ANI (ANIP): Can the Stock Really Move This High?
10:55am, Thursday, 12'th Mar 2026
The mean of analysts' price targets for ANI (ANIP) points to a 44.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in
ANI Pharmaceuticals, Inc. (ANIP) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
05:22pm, Wednesday, 11'th Mar 2026
ANI Pharmaceuticals, Inc. (ANIP) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
ANI Pharmaceuticals Targets $1.1B 2026 Revenue as Cortrophin Sales Surge, Gout Launch Set for Midyear
01:07am, Wednesday, 11'th Mar 2026
ANI Pharmaceuticals (NASDAQ: ANIP) executives used a presentation at the Leerink Partners Global Healthcare Conference to outline the company's recent performance, 2026 financial outlook, and commerci
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)
01:45pm, Monday, 09'th Mar 2026
ANI (ANIP) possesses solid growth attributes, which could help it handily outperform the market.
ANI Pharmaceuticals Targets $1B+ Sales in 2026, Pivots to Rare Disease Growth at Raymond James Conf.
01:32am, Thursday, 05'th Mar 2026
ANI Pharmaceuticals (NASDAQ: ANIP) executives outlined a growth strategy centered on expanding its rare disease business while using cash flows from its generics segment to fund further investment, du
ANI Pharmaceuticals Q4 2025: Strong Growth, But Execution Risks Emerge
08:44am, Monday, 02'nd Mar 2026
ANI Pharmaceuticals delivered strong Q4 and FY25 results, with revenue up 30% and record Cortrophin Gel growth. I see near-term risks from seasonally weaker Cortrophin sales due to insurance reverific
ANI Pharmaceuticals Q4 Earnings Call Highlights
05:04am, Monday, 02'nd Mar 2026
ANI Pharmaceuticals (NASDAQ: ANIP) reported fourth-quarter and full-year 2025 results highlighting record revenue, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS, driven by growth in its
ANI Pharmaceuticals, Inc. (ANIP) Q4 2025 Earnings Call Transcript
12:57pm, Friday, 27'th Feb 2026
ANI Pharmaceuticals, Inc. (ANIP) Q4 2025 Earnings Call Transcript
ANI (ANIP) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
10:30am, Friday, 27'th Feb 2026
Although the revenue and EPS for ANI (ANIP) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street e
ANI Pharmaceuticals Turns Profit, Rare Disease Sales Surge 50%
09:46am, Friday, 27'th Feb 2026
ANI Pharmaceuticals Inc. (NASDAQ: ANIP) shares are down early Friday following the company's strong fourth-quarter report.
ANI Pharmaceuticals (ANIP) Surpasses Q4 Earnings and Revenue Estimates
09:05am, Friday, 27'th Feb 2026
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.33 per share, beating the Zacks Consensus Estimate of $1.99 per share. This compares to earnings of $1.63 per share a year ago.
